Roles
- Assistant Professor of Clinical Medicine
- Medical Director of Adult Hemophilia Treatment Center
-
Biography
Thomas Harrington, M.D., is an Assistant Professor of Clinical Medicine in the Division of Hematology at the University of Miami Miller School of Medicine. He directs the Adult Sickle Cell Program and the adult program for the University of Miami Hemophilia Treatment Center. Dr. Harrington completed his internal medicine residency and hematology fellowship at UM/Jackson Memorial, and medical oncology at the University of Minnesota. His clinical work includes Sickle Cell and Hemophilia clinics, and he has been principal/co-investigator in numerous studies, including gene therapy in Hemophilia A. -
Education & Training
Education
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Articles & News
Excellence in Care of Sickle Cell Disease Leads to National Recognition
Sickle Cell Patient Shows No Sign of Disease After Bone Marrow Transplant at Sylvester
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 3 clinical trials.
-
A PHASE 1/2, OPEN-LABEL, ADAPTIVE, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF SB-525 (PF-07055480) (RECOMBINANT AAV2/6 HUMAN FACTOR 8 GENE THERAPY) IN ADULT SUBJECTS WITH SEVERE HEMOPHILIA A
- Principal Investigator: Thomas Harrington
- Study Phase: Phase 2
- Enrollment Status: Closed
-
The main objective of this study is to compare the safety and effects of rilzabrutinib with the safety and effects of a placebo in sickle-cell disease. This study will help the study Sponsor find out if this new treatment approach is better, the same, or worse than the usual treatment approach for your sickle-cell disease and/or placebo. To decide if it is better, the study Sponsor will be looking to see if rilzabrutinib prevents the clinical vaso-occlusive crisis.
- Principal Investigator: Thomas Harrington
- Study Phase: Phase III
- Enrollment Status: Open
-
This clinical trial is a Phase 2/3 study that will determine the recommended dose of mitapivat and evaluate the efficacy and safety of mitapivat in sickle cell disease by testing how well mitapivat works compared to placebo to increase the amount of hemoglobin in the blood and to reduce or prevent the occurrence of sickle cell pain crises. In addition, the long-term effect of mitapivat on efficacy and safety will be explored in an open-label extension portion.
- Principal Investigator: Thomas Harrington
- Study Phase: Phase II/III
- Enrollment Status: Closed